Anti-vaccine sentiment is alive and well, especially in the U.S. And it was evident in recent weeks as drugmakers revealed ...

Eli Lilly is continuing its recent pattern of tying disease awareness-raising efforts to major pop cultural moments. | Eli Lilly's latest high-profile crossovers—which include a starry TV partnership ...

A Novo Nordisk challenge has driven Regen Doctors to voluntarily discontinue compounded semaglutide product claims, adding to ...

As the researchers behind Pfizer and Astellas' Padcev and Merck's Keytruda have taken victory laps on the heels of the ...

The first of seven challenges for which Teva is seeking novel solutions revolves around human-predictive platforms for ...

Texas Attorney General Ken Paxton filed a lawsuit Thursday on behalf of the state that takes aim at “false, misleading, and ...

Bayer opened a new biotech incubator in Beijing. A first-of-its-kind biosimilar originally developed by Shanghai Henlius ...

The nods allow Regeneron to better compete with Roche, which stormed the market in 2022 with Vabysmo. The Swiss drugmaker's ...

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by ...

Just a few months after Boehringer Ingelheim broke into the oncology space with the first drug that can target a rare tumor ...

Some four years into Jemperli’s commercial lifespan, a rift has emerged between GSK subsidiary Tesaro and the potential cancer blockbuster’s original developer, AnaptysBio. | Some four years into ...

Cdymax Pharma has been slapped with a warning letter from the FDA outlining two observations against the Bangalore, ...